AI eye screening market to reach $1.17 billion by 2032

QYResearch says the global artificial intelligence eye screening system market is set to surge from $150.94 million in 2025 to $1.17 billion by 2032. Asia-Pacific is projected to be the fastest-growing region as hospitals and eye care networks adopt AI tools to speed screening and widen access.

Why it matters: - The market is moving from early adoption to routine clinical use. - AI eye screening systems can help health providers detect disease earlier, reduce specialist bottlenecks, and process more patients with less friction. - The category is becoming a commercial play for hospitals, device makers, software vendors, and investors focused on digital diagnostics.

What happened: - QYResearch released a new report on the global artificial intelligence eye screening system market covering 2026-2032. - The study says the market was valued at US$150.94 million in 2025 and is projected to reach US$1,165.99 million by 2032. - The forecast implies a 36.85% compound annual growth rate. - The report says the market is gaining traction as healthcare systems prioritize earlier detection, faster triage, and scalable screening models. - The report is available with a sample PDF and a full report link: Download the sample report and Explore the full report.

The details: - Artificial intelligence eye screening sits at the intersection of ophthalmology, medical imaging, software automation, and preventive care. - Demand is being supported by the need to identify vision-threatening conditions earlier, especially where specialist access is limited. - Wider familiarity with AI-assisted diagnostics is helping adoption across image-based clinical workflows. - The report says rising chronic disease burden, greater awareness of preventable vision loss, and more digital health investment are key growth drivers. - AI-enabled screening can support resource optimization, faster routing, and more standardized image interpretation in hospitals and clinics. - Product growth is also tied to better algorithms, broader hardware compatibility, easier interfaces, and integration with electronic care environments. - North America is projected to grow from US$53.94 million in 2025 to US$357.13 million by 2032. - Asia-Pacific is projected to grow from US$60.96 million in 2025 to US$570.08 million by 2032. - Europe remains an important market for screening modernization, medtech adoption, and cross-border clinical innovation. - In medical institutions, the market is projected to rise from US$105.08 million in 2025 to US$786.26 million by 2032. - The report identifies major vendors including Airdoc Technology, Digital Diagnostics, Optomed, Eyenuk, RetinaLyze System, VUNO, Sibionics Technology, Medimaging Integrated Solution, Aeye Health, Evolucare Technologies (OphtAI), EyRIS (SELENA+), Vistel, and RETINA-AI Health. - The top three vendors held about 42.1% of revenue in 2025.

Between the lines: - The growth story is not just about AI hype. - The report points to measurable demand for faster screening pathways and more efficient eye health programs. - Asia-Pacific stands out because large population bases, diabetes-related screening needs, and healthcare modernization are combining to accelerate uptake. - The market still has room for challengers because leadership is concentrated but not closed. - Competitive success is likely to depend on workflow fit, interoperability, evidence, and commercialization, not just algorithm accuracy.

What's next: - The report expects autonomous and semi-autonomous screening workflows to gain more traction. - Portable and point-of-care imaging formats are likely to expand the addressable market. - Vendors are expected to push further into validation, regulatory progress, broader clinical use cases, and platform compatibility. - Health systems and technology buyers will likely keep focusing on implementation support, throughput, and integration with existing care delivery. - QYResearch positions the study as a decision tool for investors, manufacturers, researchers, and strategy teams weighing market entry, product planning, partnerships, or expansion.